Time on boards
- Boards served
- 4
- Current seats
- 4
- Board service
- 15 years
- Director since
- 2023
15 years of board service in total across 4 boards, counting each seat separately. Longest: Regeneron Pharmaceuticals Inc., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Regeneron Pharmaceuticals Inc. June 12, 202676.8%
-
Prudential Financial Inc. May 12, 202697.3%
-
Prudential Financial Inc. May 13, 202594.0%
-
Neurocrine Biosciences Inc. May 22, 202494.4%
-
Prudential Financial Inc. May 14, 202495.2%
-
The Sherwin-Williams Company April 17, 202495.5%
-
Regeneron Pharmaceuticals Inc. June 9, 202375.3%
-
Prudential Financial Inc. May 9, 202393.9%
-
The Sherwin-Williams Company April 19, 202398.4%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 2, 2026 | Regeneron Pharmaceuticals Inc. | Option exercise | +7,830 | $376.69 | $2,949,483 |
| Nov 2, 2026 | Regeneron Pharmaceuticals Inc. | Open-market sale | −218 | $966.74 | $210,749 |
| Nov 2, 2026 | Regeneron Pharmaceuticals Inc. | Open-market sale | −772 | $967.38 | $746,817 |
| Nov 2, 2026 | Regeneron Pharmaceuticals Inc. | Open-market sale | −2,499 | $968.58 | $2,420,481 |
| Nov 2, 2026 | Regeneron Pharmaceuticals Inc. | Open-market sale | −3,203 | $969.50 | $3,105,309 |
| Nov 2, 2026 | Regeneron Pharmaceuticals Inc. | Open-market sale | −937 | $970.51 | $909,368 |
| Nov 2, 2026 | Regeneron Pharmaceuticals Inc. | Open-market sale | −201 | $971.31 | $195,233 |
| May 21, 2026 | Neurocrine Biosciences Inc. | Option exercise | +3,318 | — | — |
| May 12, 2026 | Prudential Financial Inc. | Option exercise | +1,765 | — | — |
| May 12, 2026 | Prudential Financial Inc. | Sold back to the company | −1,765 | $102.58 | $181,054 |
| Jan 2, 2026 | Regeneron Pharmaceuticals Inc. | Grant or award | +155 | — | — |
| Oct 30, 2025 | Regeneron Pharmaceuticals Inc. | Option exercise | +2,712 | $520.01 | $1,410,267 |
| Oct 29, 2025 | Regeneron Pharmaceuticals Inc. | Option exercise | +6,500 | $520.01 | $3,380,065 |
| Oct 29, 2025 | Regeneron Pharmaceuticals Inc. | Open-market sale | −650 | $652.68 | $424,242 |
| Oct 29, 2025 | Regeneron Pharmaceuticals Inc. | Open-market sale | −2,735 | $653.50 | $1,787,323 |
Questions about Christine A. Poon
What boards is Christine A. Poon on?
Christine A. Poon sits on the boards of Neurocrine Biosciences Inc., Prudential Financial Inc., Regeneron Pharmaceuticals Inc. and The Sherwin-Williams Company.
How long has Christine A. Poon served on boards?
Our records show at least 15 years of board service across 4 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.